News & Updates

Show Multimedia Only

Semaglutide may avert adult-onset epilepsy in patients with diabetes

01 May 2026 by

Treatment with semaglutide appears effective in reducing the risk of adult-onset epilepsy or seizures relative to sodium–glucose cotransporter-2 inhibitors (SGLT2i) and other glucose-lowering drugs (GLDs) in patients with type 2 diabetes mellitus (T2DM), according to a study presented at AAN 2026.

Semaglutide may avert adult-onset epilepsy in patients with diabetes

01 May 2026

Losing weight may protect men from having erectile dysfunction

30 Apr 2026

Men in their 40s who become or remain obese are at significantly higher risk of developing erectile dysfunction (ED), regardless of age, comorbidities, and lifestyle factors, suggests a study.

Losing weight may protect men from having erectile dysfunction

30 Apr 2026

Weight cycling in adulthood linked to increased risk of gestational weight gain

29 Apr 2026

Pregnant women with a history of weight cycling as adults are likely to experience gestational weight gain, according to a study.

Weight cycling in adulthood linked to increased risk of gestational weight gain

29 Apr 2026

Original New Drug Application Approvals by US FDA (16-31 March 2026)

29 Apr 2026

New drug applications approved by US FDA as of 16-31 March 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 March 2026)

29 Apr 2026

Original New Drug Application Approvals by US FDA (1-15 April 2026)

29 Apr 2026

New drug applications approved by US FDA as of 1-15 April 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 April 2026)

29 Apr 2026

Suboptimal use of diabetes management technology in children and adolescents with T1D

29 Apr 2026 by

A Hong Kong territory-wide study has found that despite improved glycaemic outcomes and device reimbursement, use of continuous glucose monitoring systems (CGMS) and/or automated insulin delivery (AID) systems remains suboptimal in patients ≤18 years old with type 1 diabetes (T1D), particularly among adolescents, alluding to barriers beyond cost.

Suboptimal use of diabetes management technology in children and adolescents with T1D

29 Apr 2026

Maternal obesity may elevate bile acids in breast milk

24 Apr 2026

Maternal obesity appears to increase bile acid (BA) levels in breast milk, which may have implications for neonatal digestion, maturation, and health.

Maternal obesity may elevate bile acids in breast milk

24 Apr 2026

GLP-1RAs offer histologic benefits in MASH without fibrosis progression

23 Apr 2026 by

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide and liraglutide, improves histologic outcomes in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) without compromising safety, reports a Singapore study.

GLP-1RAs offer histologic benefits in MASH without fibrosis progression

23 Apr 2026

MM780G system effectively maintains glycaemic control on no-bolus days

23 Apr 2026 by

A real-world analysis shows effective glycaemic control with the MiniMed 780G (MM780G) system—an advanced automated insulin delivery (AID) system with bolus autocorrection every 5 min—in users on no-bolus days, with more users achieving glycaemic goals when the recommended optimal settings (ROS) were used.

MM780G system effectively maintains glycaemic control on no-bolus days

23 Apr 2026

Hybrid obesity care delivers substantial benefits in real-world patients in SG

20 Apr 2026 by

A hybrid obesity care that combines physician-directed glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment and lifestyle coaching via a mobile health app yields meaningful and sustained improvements in weight and metabolic parameters in a real-world setting, as shown in a local study.

Hybrid obesity care delivers substantial benefits in real-world patients in SG

20 Apr 2026

News & Updates

Showing Endocrinology articles

Showing

Specialty:

Semaglutide may avert adult-onset epilepsy in patients with diabetes

Semaglutide may avert adult-onset epilepsy in patients with diabetes

Losing weight may protect men from having erectile dysfunction

Losing weight may protect men from having erectile dysfunction

Weight cycling in adulthood linked to increased risk of gestational weight gain

Weight cycling in adulthood linked to increased risk of gestational weight gain

Original New Drug Application Approvals by US FDA (16-31 March 2026)

Original New Drug Application Approvals by US FDA (16-31 March 2026)

Original New Drug Application Approvals by US FDA (1-15 April 2026)

Original New Drug Application Approvals by US FDA (1-15 April 2026)

Suboptimal use of diabetes management technology in children and adolescents with T1D

Suboptimal use of diabetes management technology in children and adolescents with T1D

Maternal obesity may elevate bile acids in breast milk

Maternal obesity may elevate bile acids in breast milk

GLP-1RAs offer histologic benefits in MASH without fibrosis progression

GLP-1RAs offer histologic benefits in MASH without fibrosis progression

MM780G system effectively maintains glycaemic control on no-bolus days

MM780G system effectively maintains glycaemic control on no-bolus days

Hybrid obesity care delivers substantial benefits in real-world patients in SG

Hybrid obesity care delivers substantial benefits in real-world patients in SG